cbd for polymyalgia

Cbd for polymyalgia

The best part is that their products are made fresh to order. This means that you'll never be buying a product that has been sitting on store shelves for weeks. After placing an order, you'll find a beautiful blue box on your doorstep in a matter of days!

R+R Medicinals offers many ways to save – rewards points, veteran discounts, typical holiday discounts, and more. Their subscribe and save option saves 15% on every order, so if it becomes a routine supplement, that may be your best option.

Satisfaction Guarantee

Lab reports from SC Labs, one of the nation's most respected cannabis analytics firms, are available on every product page on the R+R Medicinals website. If you're willing to dig a little bit, it's possible to find terpene information in these reports as well as information on heavy metals, pesticides, and other common hemp contaminants.

Testing

Instead of stimulating your conventional cannabinoid receptors, CBD primarily interacts with the TRPV1 and 5-HT1A receptors, which are more critically involved in pain regulation than practically any other neuroreceptors in your body. As a result, scientists believe that CBD may be a promising pain treatment while not having any significant side effects.

Management of chronic pain is difficult, and patients are often unsatisfied with the effect of treatment. 5 Drug options that are currently available may not be very safe for certain patient populations. Opioids are a problematic long-term solution for chronic pain, due to the risk they carry of significant adverse events, addiction, and overdose. 6 Opioid use was also found to be associated with more severe symptoms and unemployment in fibromyalgia. 7 Other drugs used to treat chronic pain, such as antidepressants (e.g. serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants [TCAs]), have been shown to be useful for this indication but have certain side effects (e.g. increased risk of cardiovascular events and falls with TCAs) that might limit their use in older patients. 8 One solution for long-term pain that has been studied in the context of pain relief in rheumatic diseases—but not thoroughly enough—is the use of cannabis or cannabinoids, which may potentially show therapeutic qualities as well. 9

INTRODUCTION

In another study, synovial tissue obtained from RA patients was shown to undergo attenuation and inhibition of cytokine production in response to a cannabinoid binding a cannabinoid receptor. 29 Animal models also suggest a possible therapeutic quality for cannabinoids in RA, with three studies using a murine model with collagen-induced arthritis showing a beneficial effect of the cannabinoids CBD, JWH-133, and HU-308. These substances were found to be associated with clinical improvement: CBD was associated with a decrease in cytokine release and production as well as a decrease in lymphocyte proliferation 30 ; JWH-133 was associated with a decrease in serum antibody levels, decreased cytokine production, and reduced bone destruction 31 ; and HU-308 was associated with less joint swelling and destruction, reduced synovial inflammation, along with a decrease in serum antibody levels. 32 Despite these promising results, clinical research focusing on cannabinoids’ disease-modifying qualities is still lacking.

RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, AND SYSTEMIC SCLEROSIS

In OA, a murine model with surgically induced OA showed that the severity of the disease was reduced in wild-type compared with mice that have undergone gene-deletion for a presumed relevant cannabinoid receptor. The same study also showed that treatment of wild-type mice with an agonist for the same cannabinoid receptor resulted in a partial protection against OA that did not occur in the gene-deletion group or in the wild-type placebo group. 34 In another study, the activity of an enzyme suspected of causing cartilage breakdown was reduced by the treatment of chondrocytes from OA patients with a cannabinoid. 35 Only one clinical trial assessed the use of an endocannabinoid modulator in OA for pain relief, and this was not found to be significantly more beneficial for OA-associated pain than placebo. 36 Other clinical trials assessing the use of cannabis and cannabinoids for OA are currently ongoing or are yet to be published. 37